Synthesis and biological evaluation of 1-arylsulfonyl-5-(N -hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3777-3791

  Lai, Mei Jung ^a   Huang, Han Li ^c   Pan, Shiow Lin ^a,f   Liu, Yi Min ^a   Peng, Chieh Yu ^b   Lee, Hsueh Yun ^a   Yeh, Teng Kuang ^f   Huang, Po Hsien ^d,e   Teng, Che Ming ^c   Chen, Ching Shih ^d   Chuang, Hsun Yueh ^a   Liou, Jing Ping ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d OHIO STATE UNIVERSITY   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1BENZENESULFONYL 1H INDOL 5 YL) N HYDROXYACRYLAMIDE; 3 [1 (3,4 DIMETHOXYBENZENESULFONYL) 1H INDOL 5 YL] N HYDROXYACRYLAMIDE; 3 [1 (4 FLUOROBENZENESULFONYL) 1H INDOL 5 YL] N HYDROXYACRYLAMIDE; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; INDOLE DERIVATIVE; ISOENZYME; N HYDROXY 3 [1 (4 METHOXYBENZENESULFONYL) 1H INDOL 5 YL] ACRYLAMIDE; N HYDROXY 3 [1 (4 NITROBENZENESULFONYL) 1H INDOL 5 YL] ACRYLAMIDE; ORGANOLEAD COMPOUND; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860312887     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300197a     Document Type: Article

References (29)

1. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-1529 (Pubitemid 351438836)
2. Marks, P. A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs Expert Opin. Invest. Drugs 2010, 19, 1049-1066
3. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6, 38-51 (Pubitemid 43054973)
4. Gallinari, P.; Marco, S. D.; Jones, P.; Pallaoro, M.; Steinkühler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res. 2007, 17, 195-211 (Pubitemid 46438722)
5. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 2009, 27, 5459-5468
6. Glaser, K. B. HDAC inhibitors: clinical update and mechanism-based potential Biochem. Pharmacol. 2007, 74, 659-671 (Pubitemid 47096639)
7. Marks, P. A. Discovery and development of SAHA as an anticancer agent Oncogene 2007, 26, 1351-1356 (Pubitemid 46328465)
8. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R. W.; Gardner, E. R.; Figg, W. D.; Bates, S. E. Expert Rev. Anticancer Ther. 2010, 10, 997-1008
9. Atadja, P. Development of the pan-HDAC inhibitor panobinostat (LBH589): success and challenges Cancer Lett. 2009, 280, 233-241
10. Plumb, J. A.; Finn, P. W.; Williams, R. J.; Bandara, M. J.; Romero, M. R.; Watkins, C. J.; Thangue, N. B. L.; Brown, R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther. 2003, 2, 721-728
11. Wang, H.; Yu, N.; Chen, D.; Lee, K. C. L.; Lye, P. L.; Chang, J. W. W.; Deng, W.; Ng, M. C. Y.; Lu, T.; Khoo, M. L.; Poulsen, A.; Sangthongpitag, K.; Wu, X.; Hu, C.; Goh, K. C.; Wang, X.; Fang, L.; Goh, K. L.; Khng, H. H.; Goh, S. K.; Yeo, P.; Liu, X.; Bonday, Z.; Wood, J. M.; Dymock, B. W.; Ethirajulu, K.; Sun, E. T. J. Med. Chem. 2011, 54, 4694-4720
12. Novotny-Diermayr, V.; Sangthongpitag, K.; Hu, C. Y.; Wu, X.; Sausgruber, N.; Yeo, P.; Greicius, G.; Pettersson, S.; Liang, A. L.; Loh, Y. K.; Bonday, Z.; Goh, K. C.; Hentze, H.; Hart, S.; Wang, H.; Ethirajulu, K.; Wood, J. M. Mol. Cancer Ther. 2010, 9, 642-652
13. Ma, X.; Ezzeldin, H. H.; Diasio, R. B. Histone deacetylase inhibitors current status and overview of recent clinical trials Drugs 2009, 69, 1911-1934
14. Wagner, J. M.; Hackanson, B.; Lübbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin. Epigenet. 2010, 1, 117-136
15. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-1529 (Pubitemid 351438836)
16. Venugopal, B.; Evans, T. R. J. Developing histone deacetylase inhibitors as anti-cancer therapeutics Curr. Med. Chem. 2011, 18, 1658-1671
17. Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; Wang, C. C.; Yang, Y. N.; Chang, J. Y.; Lee, S. J.; Hsieh, H. P. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents J. Med. Chem. 2004, 47, 4247-4257
18. Liou, J. P.; Wu, C. Y.; Hsieh, H. P.; Chang, C. Y.; Chen, C. M.; Kuo, C. C.; Chang, J. Y. 4- and 5-Aroylindoles as Novel Classes of Potent Antitubulin Agents J. Med. Chem. 2007, 50, 4548-4552
19. Liou, J. P.; Wu, Z. Y.; Kuo, C. C.; Chang, C. Y.; Lu, P. Y.; Chen, C. M.; Hsieh, H. P.; Chang, J. Y. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors J. Med. Chem. 2008, 51, 4351-4355
20. Liou, J. P.; Mahindroo, N.; Chang, C. W.; Guo, F. M.; Lee, S. W. H.; Yeh, T. K.; Tan, U. K.; Kuo, C. C.; Chang, Y. W.; Lu, P. H.; Tung, Y. S.; Chang, J. Y.; Hsieh, H. P. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents ChemMedChem 2006, 1, 1106-1118 (Pubitemid 44622251)
21. Lee, H. Y.; Chang, J. Y.; Chang, L. Y.; Lai, W. Y.; Lai, M. J.; Shih, K. H.; Kuo, C. C.; Chang, C. Y.; Liou, J. P. Concise syntheses of N -aryl-5,6,7-trimethoxyindoles as antimitoic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation Org. Biomol. Chem. 2011, 9, 3154-3157
22. Lai, M. J.; Kuo, C. C.; Yeh, T. K.; Hsieh, H. P.; Chen, L. T.; Pan, W. Y.; Hsu, K. Y.; Chang, J. Y.; Liou, J. P. Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents ChemMedChem 2009, 4, 588-593
23. Lai, M. J.; Chang, J. Y.; Lee, H. Y.; Kuo, C. C.; Lin, M. H.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Shey, K. S.; Liou, J. P. Synthesis and biological evaluation of 1-(4′-indolyl and 6′-quinolinyl) indoles as a new class of potent anticancer agents Eur. J. Med. Chem. 2011, 46, 3623-3629
24. Mahboobi, S.; Sellmer, A.; Höcher, H.; Garhammer, C.; Pongratz, H.; Maier, T.; Ciossek, T.; Beckers, T. 2-Aroylindoles and 2-arolbenzofurans with N -hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors J. Med. Chem. 2007, 50, 4405-4418 (Pubitemid 47378838)
25. Hassig, C. A.; Symons, K. T.; Guo, X.; Nguyen, P. M.; Annable, T.; Wash, P. L.; Payne, J. E.; Jenkins, D. A.; Bonnefous, C.; Trotter, C.; Wang, Y.; Anzola, J. V.; Milkova, E. L.; Hoffman, T. Z.; Dozier, S. J.; Wiley, B. M.; Saven, A.; Malecha, J. W.; Davis, R. L.; Muhammad, J.; Shiau, A. K.; Noble, S. A.; Rao, T. S.; Smith, N. D.; Hager, J. H. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther. 2008, 7, 1054-1065
26. Olsen, C. A.; Ghadiri, M. R. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides J. Med. Chem. 2009, 52, 7836-7846
27. Wu, S. Y.; Pan, S. L.; Chen, T. H.; Liao, C. H.; Huang, D. Y.; Guh, J. H.; Chang, Y. L.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway Br. J. Pharmacol. 2008, 155, 505-513
28. Tsai, A. C.; Pan, S. L.; Sun, H. L.; Wang, C. Y.; Peng, C. Y.; Wang, S. W.; Chang, Y. L.; Kuo, S. C.; Lee, K. H.; Teng, C. M. CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation J. Biol. Chem. 2010, 285, 5497-5506
29. Tsai, A. C.; Pan, S. L.; Liao, C. H.; Guh, J. H.; Wang, S. W.; Sun, H. L.; Liu, Y. N.; Chen, C. C.; Shen, C. C.; Chang, Y. L.; Teng, C. M. Moscatilin, a bibenzyl derivative from the India orchid Dendrobrium loddigesii, suppresses tumor angiogenesis and growth in vitro and in vivo Cancer Lett. 2010, 292, 163-170